Yusuke Demizu1, Dongcun Jin2, Nor Shazrina Sulaiman2, Fumiko Nagano2, Kazuki Terashima2, Sunao Tokumaru2, Takashi Akagi3, Osamu Fujii4, Takashi Daimon5, Ryohei Sasaki6, Nobukazu Fuwa7, Tomoaki Okimoto2. 1. Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan. Electronic address: y_demizu@nifty.com. 2. Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan. 3. Department of Radiation Physics, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan. 4. Department of Radiation Oncology, Hakodate Goryokaku Hospital, Hakodate, Hokkaido, Japan. 5. Department of Biostatistics, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan. 6. Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan. 7. Department of Radiation Oncology, Ise Red Cross Hospital, Ise, Mie, Japan.
Abstract
PURPOSE: To retrospectively analyze the treatment outcomes of particle therapy using protons or carbon ions for unresectable or incompletely resected bone and soft tissue sarcomas (BSTSs) of the pelvis. METHODS AND MATERIALS: From May 2005 to December 2014, 91 patients with nonmetastatic histologically proven unresectable or incompletely resected pelvic BSTSs underwent particle therapy with curative intent. The particle therapy used protons (52 patients) or carbon ions (39 patients). All patients received a dose of 70.4 Gy (relative biologic effectiveness) in 32 fractions (55 patients) or 16 fractions (36 patients). RESULTS: The median patient age was 67 years (range 18-87). The median planning target volume (PTV) was 455 cm3 (range 108-1984). The histologic type was chordoma in 53 patients, chondrosarcoma in 14, osteosarcoma in 10, malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma in 5, and other in 9 patients. Of the 91 patients, 82 had a primary tumor and 9 a recurrent tumor. The median follow-up period was 32 months (range 3-112). The 3-year rate of overall survival (OS), progression-free survival (PFS), and local control was 83%, 72%, and 92%, respectively. A Cox proportional hazards model revealed that chordoma histologic features and a PTV of ≤500 cm3 were significantly associated with better OS, and a primary tumor and PTV of ≤500 cm3 were significantly associated with better PFS. Ion type and number of fractions were not significantly associated with OS, PFS, or local control. Late grade ≥3 toxicities were observed in 23 patients. Compared with the 32-fraction protocol, the 16-fraction protocol was associated with significantly more frequent late grade ≥3 toxicities (18 of 36 vs 5 of 55; P<.001). CONCLUSIONS: Particle therapy using protons or carbon ions was effective for unresectable or incompletely resected pelvic BSTS, and the 32-fraction protocol was effective and relatively less toxic. Nevertheless, a longer follow-up period is needed to confirm these results.
PURPOSE: To retrospectively analyze the treatment outcomes of particle therapy using protons or carbon ions for unresectable or incompletely resected bone and soft tissue sarcomas (BSTSs) of the pelvis. METHODS AND MATERIALS: From May 2005 to December 2014, 91 patients with nonmetastatic histologically proven unresectable or incompletely resected pelvic BSTSs underwent particle therapy with curative intent. The particle therapy used protons (52 patients) or carbon ions (39 patients). All patients received a dose of 70.4 Gy (relative biologic effectiveness) in 32 fractions (55 patients) or 16 fractions (36 patients). RESULTS: The median patient age was 67 years (range 18-87). The median planning target volume (PTV) was 455 cm3 (range 108-1984). The histologic type was chordoma in 53 patients, chondrosarcoma in 14, osteosarcoma in 10, malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma in 5, and other in 9 patients. Of the 91 patients, 82 had a primary tumor and 9 a recurrent tumor. The median follow-up period was 32 months (range 3-112). The 3-year rate of overall survival (OS), progression-free survival (PFS), and local control was 83%, 72%, and 92%, respectively. A Cox proportional hazards model revealed that chordoma histologic features and a PTV of ≤500 cm3 were significantly associated with better OS, and a primary tumor and PTV of ≤500 cm3 were significantly associated with better PFS. Ion type and number of fractions were not significantly associated with OS, PFS, or local control. Late grade ≥3 toxicities were observed in 23 patients. Compared with the 32-fraction protocol, the 16-fraction protocol was associated with significantly more frequent late grade ≥3 toxicities (18 of 36 vs 5 of 55; P<.001). CONCLUSIONS: Particle therapy using protons or carbon ions was effective for unresectable or incompletely resected pelvic BSTS, and the 32-fraction protocol was effective and relatively less toxic. Nevertheless, a longer follow-up period is needed to confirm these results.
Authors: Joaquim Soares do Brito; Miguel Esperança-Martins; André Abrunhosa-Branquinho; Cecilia Melo-Alvim; Raquel Lopes-Brás; João Janeiro; Dolores Lopez-Presa; Isabel Fernandes; José Portela; Luis Costa Journal: Cancers (Basel) Date: 2022-05-22 Impact factor: 6.575
Authors: Brian L Dial; David L Kerr; Alexander L Lazarides; Anthony A Catanzano; Cindy L Green; Thomas Risoli; Dan G Blazer; Rory C Goodwin; Brian E Brigman; William C Eward; Nicole A Larrier; David G Kirsch; Sergio A Mendoza-Lattes Journal: Spine (Phila Pa 1976) Date: 2020-06-15 Impact factor: 3.241
Authors: Yagiz U Yolcu; Jad Zreik; Waseem Wahood; Atiq Ur Rehman Bhatti; Mohamad Bydon; Matthew T Houdek; Peter S Rose; Anita Mahajan; Ivy A Petersen; Michael G Haddock; Safia K Ahmed; Nadia N Laack; Krishan Jethwa; Elizabeth B Jeans; Reiko Imai; Shigeru Yamada; Robert L Foote Journal: JAMA Netw Open Date: 2022-01-04